Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies

Academic Article

Abstract

  • © 2020 American Academy of Dermatology, Inc. Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 2% of the world's population. In this guideline, we focus the discussion on systemic, nonbiologic medications for the treatment of this disease. We provide detailed discussion of efficacy and safety for the most commonly used medications, including methotrexate, cyclosporine, and acitretin, and provide recommendations to assist prescribers in initiating and managing patients on these treatments. Additionally, we discuss newer therapies, including tofacitinib and apremilast, and briefly touch on a number of other medications, including fumaric acid esters (used outside the United States) and therapies that are no longer widely used for the treatment of psoriasis (ie, hydroxyurea, leflunomide, mycophenolate mofetil, thioguanine, and tacrolimus).
  • Digital Object Identifier (doi)

    Author List

  • Menter A; Gelfand JM; Connor C; Armstrong AW; Cordoro KM; Davis DMR; Elewski BE; Gordon KB; Gottlieb AB; Kaplan DH
  • Start Page

  • 1445
  • End Page

  • 1486
  • Volume

  • 82
  • Issue

  • 6